x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0230265
| Product Information | |
|---|---|
| CAS No. | 1362850-20-1 |
| Formula | C23H14ClF3N6O |
| Molecular Weight | 482.85 |
| SMILES | [O-][N+]1=CC=CC(=C1)C2=NC3=C(Cl)C=CC=C3C=C2C(NC4=C5N=CC=CC5=NC=N4)C(F)(F)F |
| Target | PI3Kδ |
| Product Description | Seletalisib is a novel small-molecule inhibitor of PI3Kδ with an IC50 value of 12 nM and shows significant selectivity to PI3Kδ with respect to the other class I PI3K isoforms (between 24- and 303-fold). |
| Format & Storage | |
|---|---|
| Purity | > 98% |
| Shipping | Shipped on dry ice. |
| Storage | Powder: -20 °C, 3 years; 4 °C, 2 years In solvent: -80 °C, 6 months; -20 °C, 1 month |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
